What is PMOS?

What is PMOS?

Despite what the name suggests, Polyendocrine Metabolic Ovarian Syndrome isn’t just about ovaries—or cysts, for that matter. In fact, many people diagnosed with PMOS don’t have any ovarian cysts at all. Confusing? You’re not alone. The name dates back to how the condition was first described, but science has come a long way since then. Today, we understand that PCOS is really a complex hormonal and metabolic condition that affects far more than reproductive health.

At its core, PMOS is about hormonal imbalance. When key hormones like insulin, androgens (like testosterone), and others are out of sync, they can create a domino effect throughout the body. This hormonal miscommunication can lead to irregular periods, acne, weight changes, hair loss or excess hair growth, difficulty with ovulation or fertility—and that’s just the shortlist. But here’s the thing: PMOS doesn’t follow a single pattern. Some women experience textbook symptoms. Others don’t fit the mold at all. That’s part of what makes PMOS so challenging—and why understanding your unique experience matters.

So, how can the PMOS Association help?

We’re here to offer more than definitions. We’re here to offer direction. Whether you’re newly diagnosed, still searching for answers, or years into your journey and feeling stuck, we’re committed to helping you make sense of PMOS—and make progress.

Here’s what you’ll find at PMOSA:

  • Reliable, science-backed information about what PMOS is (and isn’t)

  • 💬 Supportive communities of people who understand exactly what you’re going through

  • 🧬 Resources for navigating fertility, metabolic health, nutrition, and more

  • 🧠 Education for providers who want to better support their PMOS patients

  • 🙋‍♀️ Advocacy to make sure PMOS is recognized, researched, and respected

No fluff. No fad cures. Just real support, grounded in evidence and compassion.

At PMOSA, we believe every person with PCOS deserves to be informed, empowered, and heard. Wherever you are in your journey, we’re honored to walk with you.

pcos

pcos: Latest results from PubMed

Heat-processed rodent chow alters nutritive content and improves metabolic outcomes in insulin-resistant female mice

INTRODUCTION: Animal research diets are often autoclaved for sterilization. Autoclaved chow can also serve as a model for investigating the health effects of heat-processed foods. Emerging evidence finds that heat-processed foods adversely affect human health. We hypothesized that autoclaved chow would further impair metabolism in a mouse model of androgen-induced insulin resistance.

Published on: Wed, 24 Jun 2026 06:00:00 -0400

Authors: Adelaide E Weidner, Kenji Vann, Denise Ivey, Zachary R Sechrist, Calvin L Cole, Olga Astapova,

Associations between serum persistent organic pollutants and polycystic ovary syndrome risk: a case-control study with mediation analysis

CONCLUSION: Exposure to POPs, particularly PFOS and p,p'-DDE, was associated with elevated PCOS risk among Chinese women. Sex hormones, especially testosterone and progesterone, partially mediated these associations, suggesting hormonal disruption as a potential mechanism linking POPs exposure to PCOS.

Published on: Wed, 24 Jun 2026 06:00:00 -0400

Authors: Zekun Zhao,

Beyond Association: Mediation Roles of Lipidomics and Cytokine in PCOS Uncovered by Cross-Disciplinary Genomics

CONCLUSION: This study is the first to use MR to explore causal links between lipids, inflammatory factors, and PCOS. We identified uPA as a key mediator and uncovered 11 lipids significantly associated with PCOS, highlighting the phosphatidylcholine (18:2_20:4)-uPA-PCOS pathway. Our findings suggest targeting lipid metabolism and using phosphatidylcholine (18:2_20:4) and uPA as biomarkers and tools for evaluating therapeutic efficacy in PCOS.

Published on: Tue, 23 Jun 2026 06:00:00 -0400

Authors: Tingyu Lang, Yongxiu Yang,

A comprehensive review on Jiao-tai-wan: Traditional application, pharmacokinetics, and therapeutic mechanisms in multiple disorders

CONCLUSION: JTW serves as a promising alternative therapy for multiple nervous system diseases and metabolic disorders owing to its diverse pharmacological activities, although its clinical translation remains to be established. Further research is urgently necessary to utilize integrated systems biology approaches (such as proteomics, metabolomics, and transcriptomics) for elucidating the intricate mechanisms of JTW and uncovering the biological basis that underlies the synergistic effects of...

Published on: Tue, 23 Jun 2026 06:00:00 -0400

Authors: Fengwei Nan, Wangjun Xu, Xian Wang, Qinghe Miao, Jingwei Sun, Ran Zhao, Xi Li, Yunfeng Zhou, Xinmei Xie, Xiaobin Pang,

Polycystic ovary syndrome and breast cancer risk: a systematic review

CONCLUSIONS: Current evidence indicates a possible modest association between PMOS/PCOS and breast cancer risk, although findings remain inconclusive. Any absolute increase in risk appears limited and does not justify changes to current screening practices. Further research using standardized diagnostic criteria and improved stratification by phenotype, age, and menopausal status is warranted.

Published on: Tue, 23 Jun 2026 06:00:00 -0400

Authors: Flavia Costanzi, Stefano Palomba, Giuseppe Seminara, Aris Raahd Besharat, Donatella Caserta,

Retraction notice to "A new look at low-dose aspirin: Co-administration with tamoxifen in ovulation induction in anovulatory PCOS women" [J Gynecol Obstet Hum Reprod (2019) 673-675]

No abstract

Published on: Tue, 23 Jun 2026 06:00:00 -0400

Authors: Nisreen Khaled Aref, Waleed Ali Sayed Ahmed, Magdy Refaat Ahmed, Wael Farouk Sedik,

A 3.6:1 myo-inositol to D-chiro-inositol ratio and antioxidant-based food supplement before IVF improves fertility in women with PCOS: a pilot observational retrospective cohort study

CONCLUSION: This observational pilot study suggests that a pre-treatment with 3.6:1 MYO:DCI ratio and antioxidant-based supplement taken for at least 1 month prior to ovarian stimulation may improve oocyte quality and increase pregnancy rates. These findings, while promising, require confirmation in larger prospective trials.

Published on: Tue, 23 Jun 2026 06:00:00 -0400

Authors: Pedro Belchín Fernández, Virginia Calvente, Maria Jose Gómez Roso, Eva González Expósito, Ana Silván Bueno, Maya Aparicio Fluge, Daniel Ordoñez Pérez,

Subfertility in relation to gestational weight gain and gestational diabetes: the Norwegian Mother, Father and Child Cohort Study

STUDY QUESTION: Do gestational weight gain trajectories and risk of gestational diabetes mellitus (GDM) differ according to the underlying fecundability and use of ART?

Published on: Tue, 23 Jun 2026 06:00:00 -0400

Authors: A S D Laursen, E M Mikkelsen, V R Mitter, M C Magnus,

Unveiling the therapeutic potential of Mondia whitei (Hook.f.) skeels in polycystic ovary syndrome via network pharmacology and molecular docking

Polycystic ovary syndrome (PCOS) is a multifactorial endocrine disorder with complex pathophysiology involving reproductive and metabolic dysfunctions. This study investigates the therapeutic potential of Mondia whitei, a traditional African medicinal plant, against PCOS using an integrative in silico approach combining network pharmacology, molecular docking, and quantitative structure-activity relationship (QSAR) modelling. Fifteen bioactive phytochemicals from M. whitei were retrieved from...

Published on: Tue, 23 Jun 2026 06:00:00 -0400

Authors: Akingbolabo Daniel Ogunlakin, Owona Pascal Emmanuel, Christopher B Olowosoke, Adeleye Adegboyega Edema, Ahamefula Ansalm Ahuchaogu, Caleb Joel Nwaogwugwu, Seun Elizabeth Kuyoro, Abdullahi Adeyemi Adegoke, Tope Abraham Ibisanmi, Mubo Adeola Sonibare, Enitan Omobolanle Adesanya, Ajibola David Adelakun, Oluwafemi Adeleke Ojo, Mojisola Abosede Bayode, Oluyomi Stephen Adeyemi,

Elevated Visceral Adiposity Index is Associated with Reproductive Endocrine Characteristics, and Adverse Pregnancy Outcomes in Chinese Women with Polycystic Ovary Syndrome

CONCLUSION: VAI is a practical, non-invasive tool for identifying metabolic dysfunction and predicting adverse pregnancy outcomes in women with PCOS, supporting its use for risk stratification and early intervention.

Published on: Tue, 23 Jun 2026 06:00:00 -0400

Authors: Baichao Shi, Jiaxing Feng, Fengjuan Lu, Muxin Guan, Jiannan Yu, Zhuwei Gao, Yu Wang, Jing Cong, Hongli Ma, Conghui Han, Wen Yang, Xiaoke Wu, Jingshu Gao,

Prevalence of Gestational Diabetes Mellitus and Its Associated Risk Factors Among Pregnant Women Attending a Tertiary Care Hospital in Bangladesh

CONCLUSION: GDM is highly prevalent among pregnant women attending tertiary care facilities in Bangladesh. Advanced maternal age, positive family history of diabetes, and PCOS are important independent predictors. Early risk-based screening and preventive interventions may help reduce maternal and fetal complications associated with GDM.

Published on: Tue, 23 Jun 2026 06:00:00 -0400

Authors: Mohammad Moin Shahid, Khadija Begum, Kaniz Rahman, Kaniz Fatema, Fatema Tuj Johora,

Cost-effectiveness of infertility treatment pathways in PCOS: where does oocyte in-vitro maturation fit?

CONCLUSION: This model highlights the role of IVM as a valuable component of PCOS infertility treatment in centres of expertise, with potential for greater impact as culture systems advance.

Published on: Mon, 22 Jun 2026 06:00:00 -0400

Authors: Linde Mostinckx, Neli Hofer, Max Lelie, Shari Mackens, Ingrid Segers, Katrien Beeckman, Michel De Vos,

Avena sativa-derived avenanthramides suppress 12-lipoxygenase activity and downstream arachidonic acid metabolites in letrozole-induced PCOS rats

Polycystic ovary syndrome (PCOS) implicates hormonal imbalance, ovulation disorders, metabolic disturbances, and chronic low-grade inflammation. In this study, we investigated the inflammation driven by 12-lipoxygenase (12-LOX)-mediated conversion of arachidonic acid to pro-inflammatory 12-hydroxyeicosatetraenoic acid (12-HETE) and the therapeutic potential of avenanthramide (AVA)-enriched oat extract and trans-resveratrol (RSV) as natural 12-LOX inhibitors. AVA-enriched extract was obtained...

Published on: Mon, 22 Jun 2026 06:00:00 -0400

Authors: Yara Walid, Raghda A Elsabbagh, Heba Handoussa, Sahar M Abdel-Maksoud,

Effect of breastfeeding on cardiometabolic risk in patients with polycystic ovary syndrome

CONCLUSION: Breastfeeding is associated with a significant reduction in long-term cardiometabolic risks in women with PCOS following complicated pregnancies. Supporting and optimizing lactation may represent a valuable non-pharmacological strategy to consider for this high-risk population.

Published on: Mon, 22 Jun 2026 06:00:00 -0400

Authors: Stefano Palomba, Giuseppe Seminara, Flavia Costanzi, Rossella Cannarella, Tiziana Russo, Fabrizio Signore, Martina Sarica, Aldo E Calogero, Donatella Caserta, Antonio Aversa,

Correction: The role of gut microbiota mediated ferroptosis in PCOS and the therapeutic potential of Chinese herbal medicine

[This corrects the article DOI: 10.3389/fmed.2026.1730795.].

Published on: Mon, 22 Jun 2026 06:00:00 -0400

Authors: Yingchun Lv, Dongqi Li, Ning Ding, Hongying Kuang,